David R. Wells - 16 Jan 2025 Form 4 Insider Report for HeartSciences Inc. (HSCS)

Reporting relationship: Director
Issuer ticker: HSCS
Reported as of: 16 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jan 2025, 17:17:26 UTC
Prior SEC filing: 17 Oct 2023
Next SEC filing: 11 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Andrew Simpson, Attorney-in-fact

Key filing fact

David R. Wells filed Form 4 for HeartSciences Inc. (HSCS) on 21 Jan 2025.

Key facts

This page summarizes David R. Wells's Form 4 filing for HeartSciences Inc. (HSCS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jan 2025, 17:17.

Change

Previous filing in this sequence was filed on 17 Oct 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HSCS transaction Derivative

Employee Stock Option (Right to Buy)

Award

Transaction value
Shares: +6,000
Change %
Price
Shares after: 6,000
Date: 16 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,000
Exercise price: $3.33
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These options were granted to the Reporting Person effective as of January 16, 2025 (the "Effective Date"), pursuant to the approval of the compensation committee of the Issuer's board of directors.

Footnote F2

The options shall vest and be exercisable as follows: one-fourth of the options vested on the Effective Date and the remainder of the options shall vest in equal increments thereafter on each successive three-month anniversary of the Effective Date, subject to the Reporting Person's continued service on the Board through each applicable vesting date and subject to the terms of the Issuer's 2023 Equity Incentive Plan (the "2023 Plan").

Footnote F3

These options expire ten years from the Effective Date, unless terminated sooner in accordance with the Issuer's 2023 Plan or the underlying options grant agreement.